00:25 , Jun 16, 2018 |  BioCentury  |  Product Development

NSCLC disrupted

This year’s ASCO made clear that PD-1 inhibitors have supplanted chemotherapy as standard of care in first-line metastatic NSCLC. The unanticipated consequence is the knock-on effects for companies with studies under way in both first-...
07:00 , Jun 22, 2015 |  BioCentury  |  Strategy

Getting to goal

Bringing in a new CMO with a proven track record in cancer looks like AstraZeneca plc's best shot at recovering from a string of setbacks and hitting the lofty approval and revenue targets it set...
07:00 , Jun 9, 2014 |  BioCentury  |  Product Development

Sum of PARPs

Data for olaparib plus cediranib presented at the American Society of Clinical Oncology meeting show the ovarian cancer therapies may be able to achieve unprecedented gains in progression-free survival when used in combination. Whether the...